The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2025 | The prognostic utility of MRD in CD34+ cells in MDS after alloSCT
In this interview, Carolin Lindholm, MD, PhD(c), Karolinska Institute, Solna, Sweden, discusses the value of measurable residual disease (MRD) as a biomarker in myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation (alloSCT). Dr Lindholm highlights that there is an unmet need for sensitive markers in the clinic for MDS and that her project aims to redefine the method for detecting MRD in CD34+ cells, which are thought to harbor the source of relapse. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
My main research focus is MRD in MDS, so measurable residual disease in myelodysplastic syndromes. And there’s an unmet need of sensitive markers in the clinic for MDS. However, a lot of research has shown that there’s a prognostic value for MRD in MDS, and the most recent EBMT international expert recommended the usage of MRD post-transplant. So we have already in a Nordic study shown the prognostic value of MRD in MDS, and my project that I’m presenting here at the EHA focuses on redefining the method that was used in this project...
My main research focus is MRD in MDS, so measurable residual disease in myelodysplastic syndromes. And there’s an unmet need of sensitive markers in the clinic for MDS. However, a lot of research has shown that there’s a prognostic value for MRD in MDS, and the most recent EBMT international expert recommended the usage of MRD post-transplant. So we have already in a Nordic study shown the prognostic value of MRD in MDS, and my project that I’m presenting here at the EHA focuses on redefining the method that was used in this project.
So I have used the same patient material and analyzed MRD in CD34+ cells, so stem cells, where we suppose that the source of relapse for the MDS disease would be harbored. So in my study we could see that MRD positivity occurred at the same time points or even earlier and that the clonal involvement was significantly higher in the sorted cells. And what’s mainly different from previous publications that have already shown the prognostic value of MRD in stem cells is that this method that we have used is a method that would be used in the clinic. It would be a method that could be clinically applicable in the lab, since this is a method that is already in clinical use for chimerism analysis, for example.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
